JP2023539356A5 - - Google Patents

Info

Publication number
JP2023539356A5
JP2023539356A5 JP2023514163A JP2023514163A JP2023539356A5 JP 2023539356 A5 JP2023539356 A5 JP 2023539356A5 JP 2023514163 A JP2023514163 A JP 2023514163A JP 2023514163 A JP2023514163 A JP 2023514163A JP 2023539356 A5 JP2023539356 A5 JP 2023539356A5
Authority
JP
Japan
Prior art keywords
seq
amino acids
protein
modified
coronavirus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023514163A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023539356A (ja
JP7874621B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2021/051201 external-priority patent/WO2022047575A1/en
Publication of JP2023539356A publication Critical patent/JP2023539356A/ja
Publication of JP2023539356A5 publication Critical patent/JP2023539356A5/ja
Application granted granted Critical
Publication of JP7874621B2 publication Critical patent/JP7874621B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023514163A 2020-09-01 2021-08-31 改変コロナウイルス構造タンパク質 Active JP7874621B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063073327P 2020-09-01 2020-09-01
US63/073,327 2020-09-01
US202163211716P 2021-06-17 2021-06-17
US63/211,716 2021-06-17
PCT/CA2021/051201 WO2022047575A1 (en) 2020-09-01 2021-08-31 Modified coronavims structural protein

Publications (3)

Publication Number Publication Date
JP2023539356A JP2023539356A (ja) 2023-09-13
JP2023539356A5 true JP2023539356A5 (cg-RX-API-DMAC7.html) 2024-09-17
JP7874621B2 JP7874621B2 (ja) 2026-06-16

Family

ID=80492282

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023514163A Active JP7874621B2 (ja) 2020-09-01 2021-08-31 改変コロナウイルス構造タンパク質

Country Status (12)

Country Link
US (1) US20240226271A1 (cg-RX-API-DMAC7.html)
EP (1) EP4208484A4 (cg-RX-API-DMAC7.html)
JP (1) JP7874621B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230079057A (cg-RX-API-DMAC7.html)
AU (1) AU2021335378A1 (cg-RX-API-DMAC7.html)
CA (1) CA3191257A1 (cg-RX-API-DMAC7.html)
IL (1) IL300958A (cg-RX-API-DMAC7.html)
MX (1) MX2023002505A (cg-RX-API-DMAC7.html)
PY (1) PY2175039A (cg-RX-API-DMAC7.html)
TW (1) TW202229317A (cg-RX-API-DMAC7.html)
UY (1) UY39400A (cg-RX-API-DMAC7.html)
WO (1) WO2022047575A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022322270A1 (en) * 2021-08-04 2024-03-21 The University Of Melbourne Vaccine construct and uses thereof
CN120957743A (zh) * 2022-12-16 2025-11-14 金纽斯生物科技公司 多抗原rna sars-cov-2疫苗及相关方法
WO2025106425A1 (en) * 2023-11-13 2025-05-22 University Of Florida Research Foundation, Incorporated Immunogenic composition and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI526539B (zh) * 2010-12-22 2016-03-21 苜蓿股份有限公司 植物中生產類病毒顆粒(vlp)的方法及以該方法生產之vlp
WO2018115527A2 (en) * 2016-12-23 2018-06-28 Curevac Ag Mers coronavirus vaccine

Similar Documents

Publication Publication Date Title
AU2022279441A1 (en) Novel multivalent nanoparticle-based vaccines
US20240075125A1 (en) Expression systems
KR102920353B1 (ko) 나노입자-기반 인플루엔자 바이러스 백신 및 이의 용도
EP2536425B1 (en) Vaccines for use in the prophylaxis and treatment of influenza virus disease
CA2730171C (en) Soluble recombinant influenza antigens
Phan et al. ELP ylated haemagglutinins produced in tobacco plants induce potentially neutralizing antibodies against H5N 1 viruses in mice
EP3160501B1 (en) Influenza virus hemagglutinin protein as a vaccine antigen
JP2013526849A5 (cg-RX-API-DMAC7.html)
TW201520221A (zh) 穩定化可溶性融合前rsv f多肽
JP2012521786A5 (cg-RX-API-DMAC7.html)
Lin et al. Glycan masking of hemagglutinin for adenovirus vector and recombinant protein immunizations elicits broadly neutralizing antibodies against H5N1 avian influenza viruses
JP2011527181A5 (cg-RX-API-DMAC7.html)
Mbewana et al. Production of H5N1 influenza virus matrix protein 2 ectodomain protein bodies in tobacco plants and in insect cells as a candidate universal influenza vaccine
JP2008524261A5 (cg-RX-API-DMAC7.html)
EP2956473A1 (en) Oligomeric influenza immunogenic compositions
CN109966483A (zh) 一种基于铁蛋白的多抗原通用流感疫苗及其制备方法和应用
CN118725052A (zh) 具有稳定融合前构象的呼吸道合胞病毒f蛋白
WO2024018364A1 (en) Enveloped virus like particles comprising sars-cov-2 s protein
Karyagina et al. Development of a platform for producing recombinant protein components of epitope vaccines for the prevention of COVID-19
WO2009133463A1 (en) Soluble influenza vaccine
WO2016179099A4 (en) Modified h7 hemagluttinin glycoprotein of the influenza a/shanghai/2/2013 h7 sequence
Kotlyarov et al. Development of recombinant vaccine against A (H1N1) 2009 influenza based on virus-like nanoparticles carrying the extracellular domain of M2 protein
KR102259974B1 (ko) 재조합 항원을 이용하여 목적 항원 특이적인 항체를 제조하는 방법
Wei Design and Development of Influenza Neuraminidase Nanoparticle Vaccine
Utomo et al. An Overview of Recent Developments in the Application of Antigen Displaying Vaccine Platforms: Hints for Future SARS-CoV-2 VLP Vaccines. Vaccines 2023, 11, 1506